New hope for kids with rare Muscle-Weakening disease: drug trial launches
NCT ID NCT06987539
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 33 times
Summary
This study tests a drug called inebilizumab in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, how safe it is, and if it helps control symptoms. About 15 children will take part in this open-label trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Neuromuscular Center
RECRUITINGAustin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.